056090.KQ U&I Corporation
- Market cap
- KRW 90.6B
- P/E
- 13.8x
- P/B
- 0.95x
- ROE
- 3.6%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 056090.KQ undervalued?
Graham number056090.KQ trades 23.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
U&I Corporation fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (3.6%), below 10%.
ROA 0/1
Return on assets (2.6%) is below the industry median (6.2%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (10,801.9%) is above the industry median (0.5%).
Revenue Growth 1/2
Revenue grew 4.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (13.3%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (13.8x) is above the market median (11.3x).
PE vs Industry 0/1
PE (13.8x) is above the industry median (7.6x).
PBV 0/1
Price to book (0.9x) is above the industry median (0.7x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 13.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
U&I Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About U&I Corporation
CG MedTech Co.,Ltd. researches, develops, manufactures, and sale of orthopedic medical devices in the healthcare service market. The company offers headless screws, cortex screws, and K-wires and pin; Aspiron and Maxima anterior cervical plate systems for use in anterior interbody screw/plate fixation of the cervical spine; ANAX OCT spinal system, a device for spinal surgery; Velofix PEEK SA cervical cages for cervical interbody fusion; and Velofix PEEK cage; and NeoIC PEEK …
Full company profileU&I Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
U&I Corporation annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.7B | 13.3B | 31.7B | 34.8B | 27.8B | 38.1B | 41.2B | 35.0B | 34.6B | 47.2B | 56.7B |
| Gross Profit | 6.37B | 4.16B | 10.8B | 13.7B | 6.18B | 15.9B | 19.1B | 18.3B | 16.1B | 21.2B | 22.1B |
| Operating Income | -3.19B | -5.34B | -15.2B | -1.13B | -10.8B | -5.08B | 405M | 3.06B | -1.10B | 3.82B | 1.14B |
| EBITDA | - | - | - | - | - | - | -9.90B | 3.78B | 1.89B | 5.18B | 4.40B |
| Net Income | -2.08B | -6.54B | -14.7B | -1.89B | -12.3B | -4.97B | -18.5B | 1.63B | 59.7M | 6.51B | 3.46B |
| EPS | -55 | -173 | -386 | -49 | -306 | -108 | -235 | 21 | 0.58 | 63 | 33 |
| Balance Sheet | |||||||||||
| Total Assets | 66.2B | 79.1B | 74.9B | 71.1B | 64.4B | 75.1B | 141B | 79.1B | 107B | 115B | 134B |
| Total Liabilities | 7.09B | 24.8B | 35.7B | 33.1B | 37.3B | 46.5B | 83.8B | 19.2B | 20.4B | 20.8B | 37.8B |
| Shareholders' Equity | 59.1B | 54.3B | 39.2B | 38.0B | 27.1B | 28.5B | 57.7B | 60.2B | 87.2B | 94.0B | 95.8B |
| Cash & Short-term Investments | 27.8B | 25.6B | 15.1B | 5.89B | 9.84B | 20.2B | 22.5B | 12.6B | 26.9B | 10.4B | 10.3B |
| Total Debt | 3.17B | 16.6B | 12.7B | 20.9B | 6.60B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.54B | -1.54B | -2.95B | -2.11B | 2.15B | 1.28B | -5.36B | -2.48B | 1.51B | 2.61B | -6.79B |
| Capital Expenditure | 1.00B | 784M | 15.4B | 711M | 205M | 862M | 950M | 1.65B | 810M | 11.9B | 22.6B |
| Free Cash Flow | - | - | - | - | - | - | -6.31B | -4.12B | 701M | -9.33B | -29.3B |
| Ratios | |||||||||||
| ROE | -3.5% | -12.1% | -37.5% | -5.0% | -45.4% | -17.4% | -32.1% | 2.7% | 0.1% | 6.9% | 3.6% |
| ROA | -3.1% | -8.3% | -19.7% | -2.7% | -19.1% | -6.6% | -13.1% | 2.1% | 0.1% | 5.7% | 2.6% |
| Net Profit Margin | -17.8% | -49.2% | -46.5% | -5.4% | -44.2% | -13.1% | -45.0% | 4.7% | 0.2% | 13.8% | 6.1% |
| Debt to Equity | 0.05x | 0.31x | 0.32x | 0.55x | 0.24x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
U&I Corporation dividends
U&I Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Oct 7, 2026.
Who owns U&I Corporation
- Insiders 40.54%
- Institutions 3.76%
- Public & others 55.70%
- Shares outstanding 20.7M
- Free float 11.8M
U&I Corporation company profile
- Company name
- U&I Corporation
- Ticker
- 056090.KQ
- ISIN
- KR7056090004
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 122
- Fiscal year end
- December
- Address
- 20, Sandan-ro, Uijeongbu-si, South Korea, 11781
- Phone
- 82 3 1860 6800
- Website
- cgmedt.com
About U&I Corporation
CG MedTech Co.,Ltd. researches, develops, manufactures, and sale of orthopedic medical devices in the healthcare service market. The company offers headless screws, cortex screws, and K-wires and pin; Aspiron and Maxima anterior cervical plate systems for use in anterior interbody screw/plate fixation of the cervical spine; ANAX OCT spinal system, a device for spinal surgery; Velofix PEEK SA cervical cages for cervical interbody fusion; and Velofix PEEK cage; and NeoIC PEEK cage, devices used with autograft or bone graft substitutes, as well as UniSpace Stand-Alone C Cage, a standalone anterior cervical interbody fusion device. It also provides Benefix interspinous fixation systems for the immobilization and stabilization of the spinous processes; ANAX 5.5 posterior spinal fixation system; ANAX 5.5 MIS System, ANAX 5.5 CT Spinal System, U&I Retractor; Perfix spinal system, a posterior and non-cervical pedicle fixation system, that includes Iliac screw, MIS system, level extension device; Spinal Hook system that provides distraction, compression, axial rotation, and anterior-posterior correction of deformities from thoracic spine to sacral spine; and Neo IC Cylindrical, Velofix TLIF cage, and Neo IC Square cage, as well as INNOVERSE spinal system. In addition, the company provides Polarfix facet screw fixation system, SECULOK interference screw and shoulder anchor; PRO-DENSE Bone graft substitute, MIIG X3 injectable graft, and OSTEOSET products, as well as LIFEGRAFT. Further, it offers Dyna Locking Trochanteric Nail; Dyna Locking Ankle Nail; Dyna Locking IM Nail; Dyna Locking Cannulated Screw; EXPEDIO balloon catheter, an interventional medical device; and L'DISQ for radicular and discogenic pain, as well as velofuse gel and putty, an injectable demineralized bone fiber. The company was formerly known as Innosys Co., Ltd. and changed its name to CG MedTech Co.,Ltd. in November 2024. The company was founded in 1993 and is headquartered in Uijeongbu-si, South Korea.
U&I Corporation management
2- Ju mi ChungChief Executive Officer
- Y. J. OhDirector of Marketing